Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

[Pharmacogenetics of clopidogrel and its clinical significance].

Panchenko EP, Komarov AL.

Kardiologiia. 2012;52(9):44-52. Review. Russian.

PMID:
23098546
2.

Proton pump inhibitors and clopidogrel.

Gaglia MA Jr, Waksman R.

Cardiovasc Ther. 2010 Jun;28(3):169-76. doi: 10.1111/j.1755-5922.2010.00143.x. Epub 2010 Mar 25. Review.

PMID:
20345494
3.

Nonresponders to clopidogrel: pharmacokinetics and interactions involved.

Giorgi MA, Di Girolamo G, González CD.

Expert Opin Pharmacother. 2010 Oct;11(14):2391-403. doi: 10.1517/14656566.2010.498820. Review.

PMID:
20828266
4.

Clopidogrel resistance: pharmacokinetic or pharmacogenetic?

Ford NF.

J Clin Pharmacol. 2009 May;49(5):506-12. doi: 10.1177/0091270009332433. Epub 2009 Feb 26. Review.

PMID:
19246723
5.

[Clinically relevant interaction between clopidogrel and proton pump inhibitors].

Alban S, Dingermann T, Griese N, Kämmerer W, Schubert-Zsilavecz M, Schulz M, Trenk D, Zagermann-Muncke P.

Pharm Unserer Zeit. 2009;38(4):370-1. doi: 10.1002/pauz.200990048. German. No abstract available.

PMID:
19572357
6.

Current status of clopidogrel pharmacogenomics.

Giusti B, Gori AM, Marcucci R, Abbate R.

Pharmacogenomics. 2012 Nov;13(15):1671-4. doi: 10.2217/pgs.12.153. No abstract available.

PMID:
23171330
7.

Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy.

Fernando H, Dart AM, Peter K, Shaw JA.

Thromb Haemost. 2011 Jun;105(6):933-44. doi: 10.1160/TH10-11-0715. Epub 2011 May 5. Review.

PMID:
21544314
8.

[Antiplatelet therapy in coronary heart disease. Some problems and achivements].

Gratsianskiĭ NA.

Kardiologiia. 2010;50(6):4-21. Review. Russian.

PMID:
20659022
9.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
10.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
11.

The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature.

Fefer P, Matetzky S.

Thromb Haemost. 2011 Aug;106(2):203-10. doi: 10.1160/TH11-04-0228. Epub 2011 Jul 12. Review.

PMID:
21792462
12.

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.

Frelinger AL 3rd, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD.

J Am Coll Cardiol. 2013 Feb 26;61(8):872-9. doi: 10.1016/j.jacc.2012.11.040. Epub 2013 Jan 16.

13.

[Safety and effectiveness of combining clopidogrel and proton pump inhibitors].

Calderón Hernanz B, Pinteño Blanco M, Puigventos Latorre F, Martínez-López I.

Farm Hosp. 2009 Nov-Dec;33(6):338-9. Spanish. No abstract available.

PMID:
20038395
14.

Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.

Furuta T, Iwaki T, Umemura K.

Br J Clin Pharmacol. 2010 Sep;70(3):383-92. doi: 10.1111/j.1365-2125.2010.03717.x.

15.

Clopidogrel and proton pump inhibitors--where do we stand in 2012?

Drepper MD, Spahr L, Frossard JL.

World J Gastroenterol. 2012 May 14;18(18):2161-71. doi: 10.3748/wjg.v18.i18.2161. Review.

16.

Antiplatelet therapy: Clopidogrel plus PPIs-a dangerous combination?

Ferreiro JL, Angiolillo DJ.

Nat Rev Cardiol. 2009 Jun;6(6):392-4. doi: 10.1038/nrcardio.2009.60.

PMID:
19471283
17.

Genetic and nongenetic factors influencing the response to clopidogrel.

Notarangelo MF, Bontardelli F, Merlini PA.

J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S1-7. doi: 10.2459/JCM.0b013e328364bb04. Review.

PMID:
24378836
18.

What's new about clopidogrel.

Cialdella P, Gustapane M, Camaioni C, Biasucci LM.

Minerva Cardioangiol. 2013 Dec;61(6):683-9. Review.

PMID:
24253460
19.

Pharmacogenetics of clopidogrel.

O'Connor SA, Hulot JS, Silvain J, Cayla G, Montalescot G, Collet JP.

Curr Pharm Des. 2012;18(33):5309-27. Review.

PMID:
22724417
20.

Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers.

Wu J, Jia LT, Shao LM, Chen JM, Zhong DD, Xu S, Cai JT.

Eur J Clin Pharmacol. 2013 Feb;69(2):179-87. doi: 10.1007/s00228-012-1329-z. Epub 2012 Jun 16.

PMID:
22706585
Items per page

Supplemental Content

Write to the Help Desk